186 related articles for article (PubMed ID: 27920362)
21. On testing simultaneously non-inferiority in two multiple primary endpoints and superiority in at least one of them.
Röhmel J; Gerlinger C; Benda N; Läuter J
Biom J; 2006 Dec; 48(6):916-33. PubMed ID: 17240652
[TBL] [Abstract][Full Text] [Related]
22. Methods for one-sided testing of the difference between proportions and sample size considerations related to non-inferiority clinical trials.
Dann RS; Koch GG
Pharm Stat; 2008; 7(2):130-41. PubMed ID: 17526060
[TBL] [Abstract][Full Text] [Related]
23. Design and semiparametric analysis of non-inferiority trials with active and placebo control for censored time-to-event data.
Kombrink K; Munk A; Friede T
Stat Med; 2013 Aug; 32(18):3055-66. PubMed ID: 23508697
[TBL] [Abstract][Full Text] [Related]
24. Evidence-based sizing of non-inferiority trials using decision models.
Lansdorp-Vogelaar I; Jagsi R; Jayasekera J; Stout NK; Mitchell SA; Feuer EJ
BMC Med Res Methodol; 2019 Jan; 19(1):3. PubMed ID: 30612554
[TBL] [Abstract][Full Text] [Related]
25. Power and sample size computations in simultaneous tests for non-inferiority based on relative margins.
Dilba G; Bretz F; Hothorn LA; Guiard V
Stat Med; 2006 Apr; 25(7):1131-47. PubMed ID: 16217842
[TBL] [Abstract][Full Text] [Related]
26. Issues on the selection of non-inferiority margin in clinical trials.
Hou Y; Wu XY; Li K
Chin Med J (Engl); 2009 Feb; 122(4):466-70. PubMed ID: 19302756
[TBL] [Abstract][Full Text] [Related]
27. Challenges and regulatory experiences with non-inferiority trial design without placebo arm.
Hung HM; Wang SJ; O'Neill R
Biom J; 2009 Apr; 51(2):324-34. PubMed ID: 19358213
[TBL] [Abstract][Full Text] [Related]
28. Non-inferiority trials: the 'at least as good as' criterion with dichotomous data.
Laster LL; Johnson MF; Kotler ML
Stat Med; 2006 Apr; 25(7):1115-30. PubMed ID: 16381070
[TBL] [Abstract][Full Text] [Related]
29. A ratio test in active control non-inferiority trials with a time-to-event endpoint.
Wang YC; Chen G; Chi GY
J Biopharm Stat; 2006; 16(2):151-64. PubMed ID: 16584064
[TBL] [Abstract][Full Text] [Related]
30. A note on the conservativeness of the confidence interval approach for the selection of non-inferiority margin in the two-arm active-control trial.
Sankoh AJ
Stat Med; 2008 Aug; 27(19):3732-42. PubMed ID: 18407575
[TBL] [Abstract][Full Text] [Related]
31. Wald tests for variance-adjusted equivalence assessment with normal endpoints.
Chen YM; Weng YT; Dong X; Tsong Y
J Biopharm Stat; 2017; 27(2):308-316. PubMed ID: 27906607
[TBL] [Abstract][Full Text] [Related]
32. A studentized permutation test for three-arm trials in the 'gold standard' design.
Mütze T; Konietschke F; Munk A; Friede T
Stat Med; 2017 Mar; 36(6):883-898. PubMed ID: 27859506
[TBL] [Abstract][Full Text] [Related]
33. Two-stage adaptive strategy for superiority and non-inferiority hypotheses in active controlled clinical trials.
Shih WJ; Quan H; Li G
Stat Med; 2004 Sep; 23(18):2781-98. PubMed ID: 15344186
[TBL] [Abstract][Full Text] [Related]
34. Simultaneous confidence interval for assessing non-inferiority with assay sensitivity in a three-arm trial with binary endpoints.
Tang N; Yu B
Pharm Stat; 2020 Sep; 19(5):518-531. PubMed ID: 32112669
[TBL] [Abstract][Full Text] [Related]
35. Design and analysis of non-inferiority mortality trials in oncology.
Rothmann M; Li N; Chen G; Chi GY; Temple R; Tsou HH
Stat Med; 2003 Jan; 22(2):239-64. PubMed ID: 12520560
[TBL] [Abstract][Full Text] [Related]
36. On non-inferiority margin and statistical tests in active control trials.
Chow SC; Shao J
Stat Med; 2006 Apr; 25(7):1101-13. PubMed ID: 16345042
[TBL] [Abstract][Full Text] [Related]
37. Some practical considerations in three-arm non-inferiority trial design.
Zhou M; Kundu S
Pharm Stat; 2016 Nov; 15(6):550-559. PubMed ID: 27681603
[TBL] [Abstract][Full Text] [Related]
38. Single-stage, three-arm, adaptive test strategies for non-inferiority trials with an unstable reference.
Brannath W; Scharpenberg M; Schmidt S
Stat Med; 2022 Nov; 41(25):5033-5045. PubMed ID: 35979723
[TBL] [Abstract][Full Text] [Related]
39. Non-inferiority and networks: inferring efficacy from a web of data.
Lin J; Gamalo-Siebers M; Tiwari R
Pharm Stat; 2016; 15(1):54-67. PubMed ID: 26639225
[TBL] [Abstract][Full Text] [Related]
40. Bayesian approach to non-inferiority trials for normal means.
Gamalo MA; Wu R; Tiwari RC
Stat Methods Med Res; 2016 Feb; 25(1):221-40. PubMed ID: 22619277
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
